Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series

Core Insights - Biomea Fusion, Inc. will participate in Citi's SMID Biotech C-Suite Fireside Chat Series on October 23, 2025 [1] - A live audio webcast of the discussion will be available on Biomea's website, with a replay accessible after the event [2] Company Overview - Biomea Fusion is a clinical-stage company focused on developing oral small molecule therapies, icovamenib and BMF-650, targeting diabetes and obesity [3] - The company addresses metabolic disorders, which affect nearly half of Americans and one-fifth of the global population [3] - Biomea's mission is to provide transformative treatments aimed at curing diabetes, obesity, and related conditions [3]